MR-107A-02
Drugtablet
NCT Number: NCT06215859
MR-107A-02 is being studied to investigate its efficacy and safety for treatment of acute pain after herniorrhaphy.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 3
Investigator site 210, Sheffield, Alabama, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Main Inclusion Criteria:
Main Exclusion Criteria:
tablet
over-encapsulated tablet
over-encapsulated tablet and/or tablet
Unilateral open inguinal herniorrhaphy with mesh under general anesthesia
Time frame: 48 hours after randomization
SPID based on a 0 to 10-point numeric rating scale with activity (NRS-A) for MR-107A-02 versus placebo.
Time frame: 7 days after randomization
Number of doses of opioid rescue medication over the combined in-patient and outpatient treatment phases MR-107A-02 versus placebo.
Time frame: 7 days after randomization
Proportion of subjects using no opioid rescue medication over the combined in-patient and outpatient treatment phases MR-107A-02 versus placebo.
Time frame: 7 days after randomization
SPID based on a 0 to 10-point numeric rating scale with activity (NRS-A) for tramadol versus placebo.
Time frame: 48 hours after randomization
SPID based on a 0 to 10-point numeric rating scale with activity (NRS-A) for MR-107A-02 versus tramadol.
Viatris Specialty LLC
Industry
Multi-Center, Randomized, Double-Blind, Placebo (Double-Dummy) and Active-Controlled, Parallel-Group Study of MR-107A-02 for the Treatment of Acute Postoperative Pain Following Herniorrhaphy
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06215820
Acute Pain, Neurologic Manifestations
Sheffield, Alabama, United States
View Trial DetailsNCT05317312
Acute Pain, Neurologic Manifestations
Salt Lake City, Utah, United States
View Trial DetailsNCT06614257
Acute Pain, Agnosia
Rome, Italy
View Trial DetailsNCT06383234
Acute Pain, Agnosia
Rome, Italy
View Trial Details